Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments-Reference-Cited by-同舟云学术

Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments

Published:2005-06 Issue:5 Volume:129 Page:607-614
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Alvares Caroline L.,Davies Faith E.,Horton Clive,Patel Gita,Powles Ray,Sirohi Bhawna,Zuha Roslin,Gatt Alex,Saso Radovan,Treleaven Jennifer G.,Dearden Claire E.,Potter Michael N.,Ethell Mark E.,Morgan Gareth J.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2005.05514.x/fullpdf

Reference34 articles.

1. Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry

2. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma

3. The role of immunomodulatory drugs in multiple myeloma

4. A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma

5. High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma.

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Melphalan delivery and co-delivery nanoformulations for cancer therapy: A comprehensive review;European Journal of Medicinal Chemistry Reports;2024-12

2. Biological relapse in multiple myeloma: Outcome and treatment strategies in a Spanish real‐world setting;HemaSphere;2024-07

3. Prognostic factors in 448 newly diagnosed multiple myeloma receiving bortezomib-based induction: impact of ASCT, transplant refusal and high-risk MM;Bone Marrow Transplantation;2024-02-21

4. Aiming for the cure in myeloma: Putting our best foot forward;Blood Reviews;2023-11

5. Prognostic Factors in 448 Newly Diagnosed Multiple Myeloma Receiving Bortezomib-based Induction: Impact of ASCT, Transplant Refusal and High-Risk MM;2023-09-08